PTC Therapeutics | PTCT - Operating Profit


PTC Therapeutics reported $45.89M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
TG Therapeutics USD 34.8M 15.7M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026